1
Clinical Trials associated with DCB-BO1301An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma
The primary study objectives are
to evaluate the safety and tolerability profiles of DCB-BO1301 and to determine the maximum tolerated dose (MTD) of DCB-BO1301 as add-on therapy to dacarbazine in subjects with advanced melanoma (Phase I)
to evaluate the efficacy profile of DCB-BO1301 at MTD or lower dose level as add-on therapy to dacarbazine in subjects with advanced melanoma in terms of progression free survival (Phase IIa)
100 Clinical Results associated with DCB-BO1301
100 Translational Medicine associated with DCB-BO1301
100 Patents (Medical) associated with DCB-BO1301
100 Deals associated with DCB-BO1301